Bayer (FRA:BAYN) has received a consensus rating of “Buy” from the twenty-three research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and fifteen have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is €116.95 ($139.23).
A number of analysts recently commented on BAYN shares. Citigroup reissued a “buy” rating on shares of Bayer in a report on Friday, February 16th. Deutsche Bank set a €125.00 ($148.81) price objective on shares of Bayer and gave the stock a “buy” rating in a report on Friday, January 19th. equinet set a €118.00 ($140.48) price target on shares of Bayer and gave the company a “buy” rating in a report on Wednesday, February 28th. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a €123.00 ($146.43) price target on shares of Bayer and gave the company a “buy” rating in a report on Thursday, April 12th.
BAYN stock opened at €103.84 ($123.62) on Monday. Bayer has a 52 week low of €91.58 ($109.02) and a 52 week high of €123.82 ($147.40).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.